KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Cash from Operations: 2009-2024

Historic Cash from Operations for Arbutus Biopharma (ABUS) over the last 16 years, with Dec 2024 value amounting to -$64.8 million.

  • Arbutus Biopharma's Cash from Operations rose 71.95% to -$5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$45.3 million, marking a year-over-year increase of 36.97%. This contributed to the annual value of -$64.8 million for FY2024, which is 24.54% up from last year.
  • Per Arbutus Biopharma's latest filing, its Cash from Operations stood at -$64.8 million for FY2024, which was up 24.54% from -$85.9 million recorded in FY2023.
  • Arbutus Biopharma's 5-year Cash from Operations high stood at -$35.4 million for FY2022, and its period low was -$85.9 million during FY2023.
  • Moreover, its 3-year median value for Cash from Operations was -$64.8 million (2024), whereas its average is -$62.0 million.
  • Per our database at Business Quant, Arbutus Biopharma's Cash from Operations spiked by 47.65% in 2022 and then slumped by 143.06% in 2023.
  • Yearly analysis of 5 years shows Arbutus Biopharma's Cash from Operations stood at -$51.4 million in 2020, then plummeted by 31.28% to -$67.5 million in 2021, then soared by 47.65% to -$35.4 million in 2022, then tumbled by 143.06% to -$85.9 million in 2023, then grew by 24.54% to -$64.8 million in 2024.